약물 전달 및 유전자 전달 기기 시장 : 기술별, 디바이스 유형별, 분자 유형별, 최종 사용자별, 용도별, 치료 영역별 시장 예측(2026-2032년)

The Drug & Gene Delivery Devices Market is projected to grow by USD 4.05 billion at a CAGR of 9.29% by 2032.

Drug & Gene Delivery Devices Introduction

Drug and gene delivery devices sit at the center of a rapidly evolving therapeutic ecosystem, connecting advanced biologics, precision medicines, vaccines, and cell and gene therapies with patients in clinically controlled, scalable, and user-friendly formats. The category spans autoinjectors, wearable injectors, infusion pumps, inhalation systems, implantable delivery platforms, microneedles, viral vector delivery, non-viral vectors, lipid nanoparticles, electroporation systems, and other enabling technologies that improve dosing accuracy, adherence, stability, and patient access.

Demand is being shaped by the growth of chronic disease management, biologic drug launches, home-based care, specialty pharmaceuticals, and the clinical expansion of gene therapies. Regulatory agencies such as the U.S. FDA and European Medicines Agency continue to emphasize combination-product quality, human factors engineering, device reliability, sterility assurance, and post-market safety, making validated device design and evidence-based delivery performance key differentiators across the drug delivery devices and gene delivery systems landscape.

Transformative Shifts Reshaping Delivery Platforms

The landscape is shifting from hospital-centered administration toward connected, patient-centric, and minimally invasive delivery. Prefilled syringes, autoinjectors, on-body injectors, smart pumps, and digital adherence tools are enabling more therapies to move into outpatient and home-care settings, while biologics with higher viscosities and larger dose volumes are accelerating innovation in wearable and high-force injection systems.

In gene delivery, the industry is moving beyond a reliance on established viral vectors toward optimized adeno-associated virus platforms, lentiviral systems, lipid nanoparticles, polymeric carriers, and targeted non-viral delivery. These shifts are supported by advances in genomic medicine, mRNA technology, payload engineering, and manufacturing analytics, but they also increase the need for scalable production, cold-chain resilience, immunogenicity management, and regulatory-grade characterization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across the drug and gene delivery device lifecycle. In discovery and formulation, AI models help screen excipients, predict nanoparticle behavior, evaluate protein stability, and optimize vector design. In device engineering, machine learning supports simulation-led design, failure-mode analysis, human factors testing, and predictive quality controls that can shorten development cycles when validated against robust experimental data.

AI is also strengthening manufacturing and post-market performance. Computer vision, sensor analytics, and predictive maintenance improve process control for sterile fill-finish, vector production, assembly, and packaging, while real-world data analytics can identify adherence patterns, infusion anomalies, and safety signals. The strongest opportunities are emerging where AI is governed by traceable data, explainable validation, cybersecurity controls, and compliance with evolving FDA, EMA, and international expectations for software, connected devices, and quality management systems.

Key Regional Insights Across Global Markets

Asia-Pacific is advancing as a major region for drug delivery devices and gene delivery technologies due to expanding biologics pipelines, government investment in biotechnology, large patient populations, and rising demand for self-administered therapies. China, Japan, South Korea, India, and Australia are strengthening clinical research, local manufacturing, and regulatory pathways for advanced therapies, while regional cost sensitivity continues to favor scalable, reliable, and value-engineered delivery platforms.

North America remains a leading innovation and commercialization hub, supported by FDA-cleared combination products, advanced biomanufacturing, clinical trial infrastructure, and a large specialty-pharmaceutical ecosystem. Europe benefits from the European Medicines Agency framework, established medtech clusters, strong biosimilar adoption, and advanced therapy medicinal product regulation, while Latin America is advancing through private healthcare expansion, vaccine infrastructure, and gradual adoption of specialty injectable therapies across Brazil, Mexico, and other major healthcare systems.

The Middle East is investing in healthcare modernization, specialty care, medical infrastructure, and localization strategies, particularly in Gulf markets, while Africa presents long-term potential linked to vaccination programs, infectious disease control, and improving cold-chain and primary-care infrastructure. Across all regions, successful market entry depends on regulatory readiness, payer evidence, device usability, temperature-controlled logistics, and partnerships that align innovative delivery technologies with local healthcare delivery models.

Key Group Insights for Strategic Expansion

ASEAN markets are gaining importance as medical tourism, local pharmaceutical production, and regional harmonization efforts improve access to injectable drugs, vaccines, biosimilars, and specialty therapies. The group offers demand for practical, cost-efficient drug delivery devices that can perform reliably in diverse healthcare settings, humid climates, and decentralized care environments.

The GCC is prioritizing healthcare transformation, domestic life sciences investment, and advanced hospital infrastructure, creating opportunities for premium drug delivery devices, connected adherence solutions, and specialty therapy platforms. The European Union remains a regulatory and innovation anchor for combination products and advanced therapy medicinal products, with medical device regulation, pharmacovigilance expectations, data protection rules, and sustainability policy influencing device design, packaging, traceability, and lifecycle management.

BRICS countries combine large patient bases with rising biologics manufacturing capacity and growing public investment in biotechnology, making affordability, technology transfer, local production, and scalable quality systems central to adoption. G7 markets continue to set quality, reimbursement, intellectual property, and clinical-evidence benchmarks for high-value drug and gene delivery platforms, while NATO countries' focus on medical readiness and secure supply chains reinforces demand for resilient manufacturing, stockpiling capabilities, cybersecurity, and dependable injectable and vaccine delivery systems.

Key Country Insights in Drug & Gene Delivery Devices

The United States leads in drug delivery device innovation, combination-product approvals, connected health adoption, and gene therapy commercialization, supported by FDA regulatory pathways, advanced clinical trial networks, and strong specialty pharmaceutical spending. Canada offers a stable regulatory environment, public health system purchasing discipline, and growing biologics adoption, while Mexico is strengthening its role in medtech manufacturing and regional supply chains. Brazil remains Latin America's largest healthcare system, with opportunities tied to biosimilars, vaccines, and injectable therapies that meet public and private payer requirements.

In Europe, the United Kingdom supports life sciences innovation through strong academic and clinical infrastructure, while Germany remains a major medtech and biopharma manufacturing center. France combines advanced hospital networks with public investment in biotechnology, and Italy and Spain contribute established pharmaceutical manufacturing, clinical research, and specialty-care demand. Russia has maintained interest in domestic pharmaceutical production and vaccine platforms, though market access, regulatory navigation, and supply-chain planning require careful risk assessment.

China is scaling biomanufacturing, clinical development, and domestic innovation in biologics and gene delivery, while India is expanding vaccine, biosimilar, and cost-efficient device capabilities. Japan's mature regulatory system and aging population support demand for safe, easy-to-use delivery devices, and South Korea is advancing through biologics manufacturing, digital health, and cell and gene therapy research. Australia provides a strong clinical trial environment, transparent regulation, and demand for high-quality delivery systems across chronic disease and specialty-care applications.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient-centric engineering, validated human factors, and lifecycle quality from the earliest stages of device and therapy development. For drug delivery devices, this means designing for dose accuracy, reduced pain, reliable activation, intuitive training, connectivity where clinically useful, and compatibility with high-viscosity biologics. For gene delivery systems, leaders should invest in vector optimization, targeted delivery, scalable analytics, and manufacturing platforms that reduce variability and improve process robustness.

Commercial success will depend on integrated evidence strategies that combine clinical outcomes, usability data, pharmacoeconomic value, and real-world performance. Companies should build regional regulatory intelligence, diversify suppliers for critical components, strengthen cold-chain and sterile manufacturing resilience, and pursue partnerships with biopharma developers, contract development and manufacturing organizations, digital health firms, and healthcare providers to accelerate adoption while maintaining compliance.

Research Methodology and Data Validation

This executive summary is built on a secondary-research framework using publicly available and verifiable sources such as regulatory agency publications, clinical trial registries, peer-reviewed literature, patent databases, healthcare policy documents, pharmacovigilance materials, and international health and trade datasets. Key reference points include FDA and EMA guidance on combination products and advanced therapies, WHO materials on vaccines and access, and recognized public data from organizations such as the World Bank, OECD, and national health agencies.

Insights are synthesized through triangulation across technology trends, regulatory developments, regional healthcare infrastructure, product commercialization patterns, and manufacturing dynamics. The methodology emphasizes data consistency, source credibility, recency, and practical relevance for decision-makers in drug delivery devices, gene delivery technologies, biopharmaceutical manufacturing, medtech investment, and healthcare strategy.

Conclusion: Delivery Innovation as a Competitive Advantage

The drug and gene delivery devices landscape is entering a phase where therapeutic innovation, device usability, digital intelligence, and manufacturing excellence are inseparable. As biologics, mRNA platforms, and cell and gene therapies expand, delivery technologies will determine how effectively advanced medicines reach patients at scale.

Organizations that combine regulatory-grade evidence, patient-centered design, AI-enabled quality systems, resilient supply chains, and region-specific commercialization strategies will be best positioned to create sustainable value. The next competitive advantage will come not only from novel therapies, but from delivery platforms that make those therapies safer, more accessible, more reliable, and more economically sustainable.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug & Gene Delivery Devices Market, by Technology

• 7.1. Hydrogel Based
• 7.2. Liposomal
• 7.3. Nanoparticle
• 7.4. Polymer Based

8. Drug & Gene Delivery Devices Market, by Device Type

• 8.1. Auto Injector
• 8.2. Infusion Pump
• 8.3. Needle Free Injector
• 8.4. Pen Injector
• 8.5. Syringe

9. Drug & Gene Delivery Devices Market, by Molecule Type

• 9.1. Biologic
  • 9.1.1. Monoclonal Antibody
  • 9.1.2. Peptide
  • 9.1.3. Recombinant Protein
• 9.2. Gene Therapy
  • 9.2.1. Non Viral
    • 9.2.1.1. Lipid Based
    • 9.2.1.2. Polymer Based
  • 9.2.2. Viral Vector
    • 9.2.2.1. Adenoviral
    • 9.2.2.2. Lentiviral
    • 9.2.2.3. Retroviral
• 9.3. Small Molecule

10. Drug & Gene Delivery Devices Market, by End User

• 10.1. Clinics
• 10.2. Home Healthcare
• 10.3. Hospitals
• 10.4. Research Laboratories

11. Drug & Gene Delivery Devices Market, by Application

• 11.1. Controlled Release
• 11.2. Smart Delivery
• 11.3. Sustained Release
• 11.4. Targeted Delivery

12. Drug & Gene Delivery Devices Market, by Therapeutic Area

• 12.1. Cardiovascular
• 12.2. Diabetes
• 12.3. Infectious Diseases
• 12.4. Oncology

13. Drug & Gene Delivery Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Drug & Gene Delivery Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Drug & Gene Delivery Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AptarGroup, Inc.
• 17.3. Bausch + Lomb Incorporated
• 17.4. Baxter International Inc.
• 17.5. Becton, Dickinson and Company
• 17.6. Camurus AB
• 17.7. Cook Medical LLC
• 17.8. Elixir Medical Corporation
• 17.9. Enable Injections, Inc.
• 17.10. Gerresheimer AG
• 17.11. Haselmeier GmbH
• 17.12. Insulet Corporation
• 17.13. Medtronic plc
• 17.14. Nipro Corporation
• 17.15. Owen Mumford Limited
• 17.16. Phillips-Medisize, LLC
• 17.17. Santen Pharmaceutical Co., Ltd.
• 17.18. SCHOTT Pharma AG & Co. KGaA
• 17.19. SHL Medical AG
• 17.20. Spectrum Plastics Group
• 17.21. Stevanato Group S.p.A.
• 17.22. Tandem Diabetes Care, Inc.
• 17.23. Teleflex Incorporated
• 17.24. Terumo Corporation
• 17.25. West Pharmaceutical Services, Inc.
• 17.26. Ypsomed Holding AG